Stockwatch: Managing Down Earnings Expectations
This article was originally published in Scrip
The first-quarter 2016 earnings season for life science companies is about to get underway and if the previous week's early quarterly earnings reports from US banks were anything to go by, expectations are not high. Indeed, even the normally optimistic investment bank analysts have been prefacing the upcoming earnings season at many companies with a good dose of caution.
You may also be interested in...
Biogen’s poor third-quarter results cannot be blamed solely on the pandemic. Pipeline attrition and underperformance in most franchises pushes all the risk onto a dubious throw of the regulatory dice.
Early in 2020, company guidance was that pandemic-related effects would have dissipated in the third quarter. Issues specific to J&J and Roche leave this broad conclusion still up in the air.
Drugs that have failed in clinical studies often come back for another go, making the same mistakes for a new cohort of investors who missed the first failure. The global pandemic is also enabling this for once- or twice-failed drugs.